Orchestra BioMed Holdings, Inc. logo

Orchestra BioMed Holdings, Inc. (OBIO) Q1 2026 Earnings

OBIO·Reported May 12, 2026·Before market open

Orchestra BioMed Holdings, Inc. reported Q1 2026 revenue of $110.0K (-56.5% YoY), missed analyst consensus of $918.7K by $808.7K. Diluted EPS came in at $-0.33 (+23.3% YoY), beat the $-0.40 consensus by $0.07.

Revenue
$110.0Kmissed by $808.7K
Consensus: $918.7K
Diluted EPS
$-0.33beat by $0.07
Consensus: $-0.40
SEC

SEC Filings

Earnings release8-K not filed yet
Quarterly report10-Q · 0001104659-26-059382

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Orchestra BioMed Holdings, Inc.'s Q1 2026 earnings report.

Orchestra BioMed Holdings, Inc. (OBIO) reported Q1 2026 earnings on May 12, 2026 before market open.

Orchestra BioMed Holdings, Inc. reported revenue of $110.0K and diluted EPS of $-0.33 for Q1 2026.

Revenue missed the consensus estimate of $918.7K by $808.7K. EPS beat the consensus estimate of $-0.40 by $0.07.

Compared to the same quarter a year prior, revenue declined 56.5% from $253.0K a year earlier and diluted EPS grew 23.3% from $-0.43.

You can read the 10-Q periodic report (0001104659-26-059382) directly on SEC EDGAR. The filing index links above go to sec.gov.